Interacting Drugs |
Dihydroergotamine vs Serotonin 5-HT1D Receptor Agonists |
Security Level |
|
Mechanism |
Serotonin 5-HT1D Receptor Agonists: Ergot Derivatives may enhance the vasoconstricting effect of Serotonin 5-HT1D Receptor Agonists. Serotonin 5-HT1D Receptor Agonists may enhance the vasoconstricting effect of Ergot Derivatives. |
Management |
Avoid combination |
Dihydroergotamine vs Serotonin 5-HT1D Receptor Agonists
Post Review about Dihydroergotamine vs Serotonin 5-HT1D Receptor Agonists Click here to cancel reply.
Other Interactions of Dihydroergotamine
Other Interactions of Serotonin 5-HT1D Receptor Agonists
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.